These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy? Potters L; Calugaru E; Jassal A; Presser J Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1014-9. PubMed ID: 16682144 [TBL] [Abstract][Full Text] [Related]
6. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy. Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887 [TBL] [Abstract][Full Text] [Related]
7. Is an 192Ir permanent seed implant feasible for prostate brachytherapy? Glasgow GP; Dogan N; Mohideen N Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis. Al-Qaisieh B; Smith DW; Brearley E; St Clair S; Bownes P Radiother Oncol; 2007 Aug; 84(2):140-7. PubMed ID: 17588696 [TBL] [Abstract][Full Text] [Related]
9. The effect of the radial function on I-125 seeds used for permanent prostate implantation. Pickett B; Pouliot J Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917 [TBL] [Abstract][Full Text] [Related]
10. Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy. Prete JJ; Prestidge BR; Bice WS; Dubois DF; Hotchkiss LA Radiat Oncol Investig; 1998; 6(2):90-6. PubMed ID: 9572685 [TBL] [Abstract][Full Text] [Related]
11. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707 [TBL] [Abstract][Full Text] [Related]
12. Prostate brachytherapy post-implant dosimetry: a comparison between higher and lower source density. Thomas CW; Kruk A; McGahan CE; Spadinger I; Morris WJ Radiother Oncol; 2007 Apr; 83(1):18-24. PubMed ID: 17368844 [TBL] [Abstract][Full Text] [Related]
13. Loose seeds vs. stranded seeds: a comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer. Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook JM Brachytherapy; 2008; 7(2):200-5. PubMed ID: 18362087 [TBL] [Abstract][Full Text] [Related]
14. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Wust P; von Borczyskowski DW; Henkel T; Rosner C; Graf R; Tilly W; Budach V; Felix R; Kahmann F Radiother Oncol; 2004 Oct; 73(1):39-48. PubMed ID: 15465144 [TBL] [Abstract][Full Text] [Related]
15. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view. Nickers P; Thissen B; Jansen N; Deneufbourg JM Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365 [TBL] [Abstract][Full Text] [Related]
16. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056 [TBL] [Abstract][Full Text] [Related]
17. Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion. Tanaka O; Hayashi S; Matsuo M; Nakano M; Uno H; Ohtakara K; Miyoshi T; Deguchi T; Hoshi H Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):614-8. PubMed ID: 17869675 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma. Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319 [TBL] [Abstract][Full Text] [Related]